Citations

Clear

371 citation(s) found for "Cho, B".

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Zhu, Ling , Cheung, Yee-Ming Melody , Mammen, Jennifer S. , Quandt, Zoe , Jones, Renisha, McDunn, Jon, Al-Bahadili, Huda , Warner, Allison Betof , Blackwell, Susan, Cho, Tracey , Dougan, Michael , Funchain, Pauline , Johnson, Douglas B. , Kennedy, Randol , Lim, Annette M. , Overton, Laura, Perdigoto, Ana Luisa , Sachithanandan, Nirupa , Spain, Lavinia , Tsai, Katy K., Reynolds, Kerry L. , Shariff, Afreen , Quandt, Zoe , Betof Warner, Allison , Funchain, Pauline , Herndon, Justine , Lim, Annette M , Tsai, Katy , Reynolds, Kerry L , Cho, Tracey A , Chiang, Cherie Ying , Gallagher, Emily J. , Hamnvik, Ole‐Petter R. , Jones, Renisha, McDunn, Jon , Angell, Trevor E. , Bancos, Irina , Calabrese, Cassandra M. , Ferreira, Michelle , Kheterpal, Meenal , Khouri, Michel G. , Lechner, Melissa G , Markova, Alina , Meara, Alexa Simon , Overton, Laura, Sharon, Elad , Yarchoan, Mark

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 15, 2025 | Volume: 13 | Issue: 10 | Pages: e011865

10.1136/jitc-2025-011865 | PMID 41093625 Get It

Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and timely can be challenging in the absence of clear categorization and standardization across oncology, endocrinology and other specialties. While existing guidelines provide some broad directions to diagnosis and management, they lack clarity on irAE-specific symptom evaluation and work-up, as well as assessment of severity. These limitations can then impact triage, time-sensitive management and care escalation to specialists such as oncoendocrinologists. The objective of this study was to develop consensus-based statements on disease definitions for E-irAEs. A core working group of endocrinologists with expertise in the oncoendocrinology field drafted a survey with statements outlining the general approach to E-irAEs, disease definition and management approach of six specific diagnoses: ir-thyroiditis thyrotoxic phase, ir-thyroiditis hypothyroidism, ir-Graves’ disease, ir-hypophysitis, ir-adrenalitis and ir-type 1 diabetes mellitus. Severity grading tables were drafted for three disease categories—“thyroid”, “pituitary and adrenal”, and “diabetes mellitus”. A two-round modified Delphi process, using the RAND/University of California Los Angeles (RAND/UCLA) Appropriateness Method, was employed. In this process, a 25-member voting panel consisting of endocrinologists, oncologists and other specialists and healthcare providers with experience in management of ICI-treated patients and irAEs was recruited. The panel rated anonymously on usability, accuracy, appropriateness or agreement of 41 items on a 9-point scale in Survey 1, after which a meeting was convened. Statements were modified based on voting results from Survey 1 and Meeting 1, and the process was repeated in Survey 2 and Meeting 2. At the end of this process, consensus was achieved for all statements. Our study findings address the gap in standardized nomenclature, clinical, laboratory and radiological evaluations, and management principles of E-irAEs. With consensus achieved from a panel of experts from a variety of disciplines, we anticipate that the statements can form the basis for standardization of the diagnostic process and improvement of patient care.
A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions
Manzano, Giovanna S. , Balaban, Denis , Zhang, Yihan , Healy, Brian C. , Chwalisz, Bart K. , Levy, Michael , Venna, Nagagopal, Stern, Barney J. , Pardo, Carlos A. , Rjeily, Nicole Bou , Redenbaugh, Vyanka , Aksamit, Allen J. , Herman, Max Joseph, Rodriguez, Elsa, Snider, Laura, Rains, Hannah G , Montalvo, Mayra , Ramirez, Sergi Martinez, Horta, Lucas, Clardy, Stacey , Cho, Tracey , Samudralwar, Rohini, Torres, Noellie Rivera, Clifford, David B. , Majed, Masoud , Zabeti, Aram , Marcucci, Samuel , Mao‐Draayer, Yang , Doty, John D. , Agyei, Paunel, Bhattacharyya, Shamik , Berger, Joseph R. , Samudralwar, Rohini D , Dunham, S Richard , Levy, Michael , Clardy, Stacey L , Bhattacharyya, Shamik , Manzano, Giovanna Sophia , Balaban, Denis T , Cho, Tracey A , Pardo, Carlos A , Venna, Nagagopal , Barreras, Paula , Flanagan, Eoin P. , Hutto, Spencer K , Herman, Max, Sammak, Sally El , Snider, Laura, Rempe, Torge , Ramirez, Sergi Martinez, Lord, Jennifer, Abdel-Wahed, Lama , Torres, Noellie Rivera, Dunham, Steven , Doty, Jon

Mayo Clinic

Annals of Clinical and Translational Neurology | September 18, 2025 | Volume: 12 | Issue: 12 | Pages: 2589-2599

10.1002/acn3.70200 | PMID 40963302 Get It

ABSTRACT Objective The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales. Methods Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers. Cases were analyzed by initial treatment. The primary outcome was T1 post‐contrast gadolinium enhancement resolution at 6 months post‐treatment. Secondary outcomes were changes in modified Rankin scale (mRS) and Expanded Disability Status Scale (EDSS) from nadir to final follow‐up. Results Two hundred two patients were identified (median diagnosis age: 47 years (IQR 39–55); male: female 1.3:1). Median nadir mRS and EDSS were 2 (IQR 2–3) and 4 (IQR 2.5–6). At initial treatment, 129 (63.9%) received prolonged corticosteroids ≥ 4 weeks (group A 1 ), 36 (17.8%) received corticosteroids < 4 weeks (B 1 ), 21 (10.4%) received corticosteroids plus sarcoidosis‐directed immunosuppressant (E), and 16 (7.9%) received corticosteroids plus non‐sarcoidosis‐directed agents (F). In 167 cases with sufficient imaging, there were no significant differences in contrast enhancement resolution at 6 months (A 1 27/106 (25.5%), B 1 9/28 (32.1%), E 5/19 (26.3%), F 5/14 (35.7%); Fisher's exact p = 0.76). There were no significant differences in changes in mRS or EDSS among treatment groups (Kruskal–Wallis p = 0.69 and 0.63, respectively) after median follow‐up of 46.5 months (IQR 18–91.3). Interpretation Different initial immunosuppression strategies did not correlate with MRI contrast enhancement resolution at 6 months or clinical scales (mRS, EDSS). However, conclusions are limited by retrospective design, imbalanced cohorts, and insensitivity of binary MRI outcomes and available clinical scales for treatment response in neurosarcoidosis.
Medical guidelines for fibrodysplasia ossificans progressiva
Kaplan, Frederick S. , Mukaddam, Mona Al , Hidalgo‐Bravo, Alberto , Brown, Matthew A. , Cali, Amanda, Crowe, C. R., Cunto, Carmen L. De, Delai, Patricia , Diecidue, Robert J. , Friedman, Clive, Grunwald, Zvi, Haga, Nobuhiko , Kitterman, Joseph A., Levy, Charles E. , Morhart, Rolf, Netelenbos, J.C., Shore, Eileen M. , Zasloff, Michael , Pignolo, Robert J. , Al Mukaddam, Mona , Hidalgo Bravo, Alberto , Brown, Matthew , Friedlander, Lisa , Hsiao, Edward C , Shore, Eileen M , Pignolo, Robert J , Kaplan, Frederick S , Baujat, Geneviève , Cho, Tae‐Joon , Crowe, Corrie, Cunto, Carmen De , Eekhoff, Elisabeth M. W. , Hsiao, Edward C. , Keen, Richard , Madhuri, Vrisha , Scott, Christiaan , Zhang, Ke‐Qin

Mayo Clinic

JBMR Plus | September 11, 2025 | Volume: 9 | Issue: 11 | Pages: No page available

10.1093/jbmrpl/ziaf150 | PMID 41143155 Get It

Abstract Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition characterized by congenital malformations of the great toes and progressive heterotopic ossification (HO) in specific anatomic patterns. Present management summarized here is focused on early diagnosis, assiduous avoidance of injury and iatrogenic harm, symptomatic amelioration of painful flare-ups, and optimization of residual function. Twenty-one members of the International Clinical Council on FOP (ICC) and seven consultants from 15 countries, chosen for their clinical expertise in FOP, developed this summary statement. Further advances in therapeutics will be based on rigorous clinical trials to assess novel and emerging treatment and prevention strategies. A detailed and updated exploration of the topics outlined in this brief perspective can be found in “The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations” which can be found on the International Clinical Council on FOP (ICC) website (www.iccfop.org).
Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms
Sigmund, Eric E. , Cho, Gene Y., Basukala, Dibash , Sutton, Olivia M. , Horvat, João V. , Mikheev, Artem , Rusinek, Henry , Gilani, Nima , Li, Xiaochun , Babb, James S , Pinker, Katja , Moy, Linda , Thakur, Sunitha B , Sigmund, Eric , Rusinek, Henry , Babb, James S. , Goldberg, Judith D. , Moy, Linda

Mayo Clinic

Radiology: Imaging Cancer | September 5, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1148/rycan.240115 | PMID 40910883 Get It

Intravoxel incoherent motion MRI parameters derived from two software packages demonstrated diagnostic value for breast cancer, with multivariable combinations of histogram metrics achieving high diagnostic accuracy.
Atomic-resolution structure of a chimeric Powassan tick-borne flavivirus
Das, Sayan , Narayanan, Anoop , Wang, Anqi , Moustafa, Ibrahim M. , Cho, Sung Hyun , Mitzel, Dana , Jose, Joyce , Hafenstein, Susan , Hafenstein, Susan L

Mayo Clinic

Science Advances | July 9, 2025 | Volume: 11 | Issue: 28 | Pages: No page available

10.1126/sciadv.adw7700 | PMID 40632869 Get It

Powassan virus (POWV) is an emerging tick-borne flavivirus for which no vaccine or antiviral treatment exists. The incidence of human infections of POWV in North America has been increasing because of the expanding distribution of the tick vector Ixodes scapularis that transmits POWV to humans. To mitigate the dangers of handling a risk group 3 human pathogen, a chimeric virus was constructed from the genetic backbone of a yellow fever virus vaccine strain 17D (YFV-17D) and the external structural proteins of POWV lineage II. The chimera had a comparable phenotype as POWV. The atomic resolution of yellow fever virus-Powassan virus chimera (yPOWV) structure was built without ambiguity, revealing surface glycans and lipid pocket factors. The similarity to other flavivirus structures and the phenotype similar to YFV-17D suggest that there could be future potential as a vaccine candidate.
Design, Development, Funding, and Implementation of the CSRS Registry
Witham, Julie M., Sasso, Rick C., Mummaneni, Praveen V., Riew, K. Daniel , Sardar, Zeeshan M. , Ray, Wilson Z. , Harrop, James S., Protopsaltis, Themistocles S. , Nassr, Ahmad, Vedentam, Aditya, Rhee, John M. , Lawrence, Brandon D. , Ludwig, Steven C. , Ghogawala, Zoher , Mummaneni, Praveen V. , Riew, Kiehyun Daniel , Cho, Samuel K. , Mesfin, Addisu

Mayo Clinic

Clinical Spine Surgery | July 2, 2025 | Volume: 39 | Issue: 3 | Pages: E153-E160

10.1097/bsd.0000000000001833 | PMID 40600728 Get It

Study Design: A national prospective cervical spine surgery registry was developed to archive radiographic studies, patient-reported outcome measures (PROMs), and surgical implant data to assess long-term safety. Objective: To describe the design, development, funding, and implementation of a cervical spine data registry for 1000 patients with myelopathy and radiculopathy. Summary of Background Data: While surgery for cervical radiculopathy and myelopathy is safe and effective, there is significant practice variation among spine surgeons. While randomized clinical trials (RCTs) can provide high-quality comparative effectiveness data, RCTs lack the ability to evaluate the safety and effectiveness of various surgical procedures and implants among heterogenous real-world patient populations. The CSRS Registry was designed to collect patient demographics, outcomes, radiographic imaging, surgical approach, and implant data for the purpose of conducting high-quality research. Methods: Patients with cervical myelopathy or radiculopathy were enrolled in the CSRS National Registry. De-identified patient data, validated PROMs, radiographic data, and implant data were collected from multiple clinical sites across the United States. Results: One thousand patients [mean age, 58 y; 456 (46%) women] were enrolled, with 31% follow-up at 1 year. Five hundred ninety-two patients were diagnosed with radiculopathy, 252 with myelopathy, and 156 with radiculopathy and myelopathy. Patients had significant improvements in their PROMs after surgery. At 1 year, the mean NDI score improved from 37.2 to 20.9 ( P <0.001). The mean self-reported P-mJOA score at baseline was 14.2 and improved to 15.2 by 1 year ( P <0.001). Baseline CSDI score was 23.6 and improved with a 1-year decrease to an average score of 13.6 ( P <0.001). There was significant improvement in PROMIS-10 Physical Health score from 41.0 to 45.9 (n=311; P <0.001) at 1-year follow-up. Conclusions: The CSRS Registry has successfully collected clinical outcomes data that is being leveraged for comparative effectiveness research and evaluations of the long-term safety and effectiveness of spinal implants.
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Janas, Anastasia , Baid, Ujjwal , Ramakrishnan, Divya , Saluja, Rachit , Ashraf, Nader, Maleki, Nazanin , Yordanov, Nikolay , Fehringer, Pascal, Gkampenis, Athanasios , Amiruddin, Raisa, Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammad, Bergquist, Timothy , Chiang, Veronica , Eddy, J. Mark , Ezhov, Ivan , Khalili, Nastaran, Jiang, Zhifan , Johanson, Elaine, Kazerooni, Anahita Fathi , Krantchev, Kiril, Linguraru, Marius George , Liu, Xinyang , Meier, Zeke, Moy, Harrison, Osenberg, Klara , Reitman, Zachary, Shinohara, Russell Takeshi, Wang, Chunhao , Shafique, Umber, Willms, Klara, Avesta, Arman , Bousabarah, Khaled , Chakrabarty, Satrajit , Gennaro, Nicolò , Holler, Wolfgang, Lost, Jan , Marcus, Daniel S. , Maresca, R, Merkaj, Sarah, Pedersen, Gabriel Cassinelli, Reppert, Marc von , Teytelboym, Oleg M., Tillmans, Niklas, Westerhoff, Malte , Youssef, Ayda , Pflüger, Irada, Perez-Carillo, Gloria J. Guzman, Memon, Fatima, Krycia, Mark, Patro, Satya Narayana , Petrović, Bojan , Schrickel, E. Brooke, Besada, Cristina , Chu, Sammy, Dusoi, Alexandru, Farage, Luciano , Fong, Amy, Gray, R. Ian, Krumpelman, Chase, Lincoln, Christie M. , Maros, Máté E. , Morón, Fanny , Nimchinsky, Esther A. , Patel, Uresh, Rohatgi, Saurabh , Sayah, Anousheh , Schwartz, Eric D. , Shiroishi, Mark S. , Valerie, Jewels, White, Matthew L. , Zohrabian, Vahe M. , Brüßeler, Melanie, Ghonim, Mohamed, Okar, Abdullah , Pasquini, L. , Soumala, Theodora, Taherzadeh, Mahsa , Vollmuth, Philipp, Foltyn, Martha , Abayazeed, Aly, Dellepiane, Francesco , Verdier, Maria Correia de , Al-Rubaiey, Sanaria, Ashraf, Kholod, Asla, Moamen M., Badawy, Mohamed , Lomer, Nima Broomand , Bukatz, Jan, Chen, Jim, Cimflová, Petra , Corr, Felix, Crawley, Alexis, Deptula, Lisa, Elakhdar, Tasneem, Shawali, Islam H., Frick, Alexandra, Haider, Muhammad Ammar , Hierro, Fátima , Jacobs, Sarah Maria, Hsieh, Kuang-chun Jim, Kersting, Katharina , Kida, Laura, Kollia, Sofia , Koukoulithras, Ioannis, Li, Xiao , Abouelatta, Ahmed, Mansour, Aya, Maria-Zamfirescu, Ruxandra-Catrinel, Marsiglia, Marcela , Mateo-Camacho, Yohana Sarahi , McArthur, Mark J., McDonnell, Olivia, McHugh, M, Moassefi, Mana , Morsi, Samah Mostafa, Munteanu, Alexander , Naqvi, Syed Raza, Nikanpour, Yalda , Alnoury, Mostafa , Nouh, Abdullah Mohamed Aly, Pappafava, Francesca, Patel, Markand D., Petrucci, S. , Rawie, Eric, Raymond, Scott B. , Roohani, Borna, Sabouhi, Sadeq, Sánchez‐García, Laura , Shaked, Zoe , Altes, Talissa A. , Isufi, Edvin , Dhemesh, Yaseen , Gass, Jaime, Thacker, Jonathan, Tarabishy, Abdul , Turner, Benjamin , Worede, Fikadu , Yousry, Sara, Lerebo, Wondwossen , Aristizábal, Alejandro , Karargyris, Alexandros , Kassem, Hasan , Sheller, Micah , Link, Katherine E. , Moawad, Ahmed W. , Ashraf, Nader, Jekel, Leon , Manteghinejad, Amirreza , Aneja, Sanjay , Anwar, Syed Muhammad, Chung, Verena , Conte, Gian Marco , Dako, Farouk , Eddy, James, Khalili, Nastaran, Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Piraud, Marie , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Kaur, Manpreet , LaMontagne, Pamela , Lin, MingDe , Maresca, Ryan, Petersen, Gabriel Cassinelli , Sotiras, Aristeidis , Godfrey, Devon , Floyd, Scott , Rauschecker, Andreas M. , Villanueva-Meyer, Javier E. , Cho, Jaeyoung , Bendszus, Martin , Brugnara, Gianluca , Cramer, Justin , Johnson, Derek R. , Kam, Anthony , Kwan, Benjamin Y. M. , Lai, Lillian M. , Lall, Neil , So, Tiffany Y. , Thompson, Gerard , Wu, Lei , Bansal, Anu , Barkhof, Frederik , Druzgal, T. Jason , Feltrin, Fabrício Stewan , Fung, Steve H. , Ikuta, Ichiro , Iv, Michael , Postma, Alida A. , Mahajan, Amit Kumar , Joyner, David , Létourneau‐Guillon, Laurent , Miller, Elka , Özsarlak, Ö. , Saha, Atin , Shih, Robert , Small, Juan E. , Tanwar, Manoj , Weinberg, Brent D. , Young, Robert J. , Azizova, Aynur , Ghonim, Mohanad , Ghonim, Mohamed, Sharifi, Yasaman , Singh, Gagandeep, Sollmann, Nico , Vollmuth, Philipp, Foltyn‐Dumitru, Martha , Malhotra, Ajay , Lohmann, Philipp , Pérez‐García, Víctor M. , Elhalawani, Hesham M. , Duarte Armindo, Rui , Asla, Moamen M., Bisschop, Jeroen , Faghani, Shahriar , Gulati, Vaibhav , Dahl, Rasmus Holmboe , McArthur, Mark, McHugh, Maire, Moassefi, Mana , Nandolia, Khanak , Petrucci, Samantha, Sanchez-Garcia, Laura M., Suthar, Pokhraj Prakashchandra , Vacca, Sebastiano , Vilanilam, George K. , Warren, Daniel, Weiss, David, Pati, Sarthak , Calabrese, Evan , Tahon, Nourel Hoda , Nada, Ayman , Velichko, Yury , Bakas, Spyridon , Rudie, Jeffrey D. , Aboian, Mariam

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: December 2025 | Pages: 204-247

10.59275/j.melba.2025-9bd3 Get It

The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. The mean scores for the teams were calculated. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. The Dice score for the winning team was 0.65 ± 0.25. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space. The Dice scores and lesion detection rates of all algorithms diminished with decreasing tumor size, particularly for tumors smaller than 100 mm3. In conclusion, algorithms for BM segmentation require further refinement to balance high sensitivity in lesion detection with the minimization of false positives and negatives. The BraTS-METS 2023 challenge successfully curated well- annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied environments and providing the tools for future development of personalized volumetric reports to patients undergoing BM treatment.
OT06 | AHOD2131: A RANDOMIZED PHASE 3 RESPONSE‐ADAPTED TRIAL COMPARING STANDARD THERAPY TO IMMUNO‐ONCOLOGY FOR CHILDREN & ADULTS WITH NEWLY DIAGNOSED STAGE I/II HODGKIN LYMPHOMA
Renfro, Lindsay A. , Keller, F., Duvall, Arndt J. , Henderson, T. O., Cho, S. Y., Milgrom, Sarah A. , Roth, Lisa , Grover, N. S., LaCasce, Ann S. , Kelly, Kara M. , Seelisch, Jennifer , Hu, Boyu , Keller, F. G., DuVall, A., Wu, Yonghui , Hoppe, Bradford S. , Grover, N. S., Kahn, Jeremy M. , Yao, Song , Parsons, Susan K. , Khan, Nadia , Vega, Raymond B. Mailhot , Hinds, Pamela S. , Allen, P. B., Evens, Andrew M. , Schöder, Heiko , Castellino, Sharon M.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_ot06 Get It

242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY
Cho, S. , Poon, Michelle, Bachy, E., Guidez, Stéphanie , Jagadeesh, Deepa , Mayer, L, Tani, M., Ambati, Srikanth, Uppala, Amulya , Brouwer‐Visser, Jurriaan , Chaudhry, A., Kim, T. M., Luminari, Stefano , Taszner, Michał , Chong, Geoffrey , Novelli, Silvana , Villasboas, José C. , Merli, Michele , Ubieto, Ana Jiménez , Tessoulin, Benoit , Tucker, David , Walewski, Jan , Yi, S., Song, Yuqin , Alonso, Aránzazu , Iskierka‐Jazdzewska, Elżbieta , Cai, James J. , Shariff, S., Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_242 Get It

373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP
Cho, S., Dieckmann, Karin , Kelly, KM, Kurch, Lars , Lai, Hollie , Mauz‐Körholz, Christine , McCarten, Kathleen M. , Steglich, J., Stoevesandt, Dietrich, Voss, Stephan D. , Milgrom, Sarah A. , Gowdy, Claire , Flerlage, Jamie E. , Seelisch, Jennifer , Palese, M., Bradshaw, Tyler , Castellino, Sharon M. , Hoppe, Bradford S. , Howard, Scott C. , Lopci, Egesta , Lucas, John T. , Pandit-Taskar, Neeta D. , Schöder, Heiko

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_373 Get It